Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotics are increasingly used for treatment of mental illnesses like schizophrenia and bipolar disorder, and considered to have fewer extrapyramidal effects than older antipsychotics. METHODS: We examined efficacy in randomised trials of bipolar disorder where the presenting episode was either depression, or manic/mixed, comparing atypical antipsychotic with placebo or active comparator, examined withdrawals for any cause, or due to lack of efficacy or adverse events, and combined all phases for adverse event analysis. Studies were found through systematic search (PubMed, EMBASE, Cochrane Library), and data combined for analysis where there was clinical homogeneity, with a special reference to trial duration. RESULTS: In five trials (2,206 patients) participants presented with a depressive episode, and in 25 trials (6,174 patients) the presenting episode was manic or mixed. In 8-week studies presenting with depression, quetiapine and olanzapine produced significantly better rates of response and symptomatic remission than placebo, with NNTs of 5-6, but more adverse event withdrawals (NNH 12). With mania or mixed presentation atypical antipsychotics produced significantly better rates of response and symptomatic remission than placebo, with NNTs of about 5 up to six weeks, and 4 at 6-12 weeks, but more adverse event withdrawals (NNH of about 22) in studies of 6-12 weeks. In comparisons with established treatments, atypical antipsychotics had similar efficacy, but significantly fewer adverse event withdrawals (NNT to prevent one withdrawal about 10). In maintenance trials atypical antipsychotics had significantly fewer relapses to depression or mania than placebo or active comparator. In placebo-controlled trials, atypical antipsychotics were associated with higher rates of weight gain of >or=7% (mainly olanzapine trials), somnolence, and extrapyramidal symptoms. In active controlled trials, atypical antipsychotics were associated with lower rates of extrapyramidal symptoms, but higher rates of weight gain and somnolence. CONCLUSION: Atypical antipsychotics are effective in treating both phases of bipolar disorder compared with placebo, and as effective as established drug therapies. Atypical antipsychotics produce fewer extrapyramidal symptoms, but weight gain is more common (with olanzapine). There is insufficient data confidently to distinguish between different atypical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 1×
“Discussion An evidence-based approach to therapy requires certain fundamentals in order to have confidence in a result, and most confidence comes from systematic review and metaanalysis of good quality randomised trials [50].”
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282 · cited 1×
“Homogeneity tests and funnel plots, though commonly used in meta-analysis, were not used here because they have been found to be unreliable [10-12].”
MethodThe number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885 · cited 1×
“treat (or harm) was calculated by the method of Cook and Sackett [15] using the pooled number of observations only when there was a statistically significant difference of relative benefit or risk (where the confidence interval did not include 1).”
MethodMeta-Analysis in Clinical Research
L'ABBÉ, K. A., DETSKY, A. S., & O'ROURKE, K. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-224 · Cited by 1,267 · cited 1×
“Instead clinical homogeneity was examined graphically [13].”
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 7×
“Most patients (80%) were in three large placebo-controlled trials [18,20,23] lasting eight weeks, one comparing olanzapine monotherapy or olanzapine plus fluoxetine with placebo, and the others comparing quetiapine monotherapy, at different target dosages, with placebo.”
BackgroundMethodInfluentialImpact of covert duplicate publication on meta-analysis: a case study
Tramèr, M. R., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (1997) · BMJ · doi:10.1136/bmj.315.7109.635 · Cited by 702 · cited 1×
“Statistical significance of any difference between numbers needed to treat for different drugs was assumed if there was no overlap of the confidence intervals, and additionally tested using the z statistic [16].”
MethodSelf-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689 · cited 1×
“Drug treatments have included lithium, anticonvulsants, and antipsychotics, but current therapies have proven inadequate for many patients; only half of bipolar patients achieve remission over two years, and half of these relapse within the two years [4].”
Background
Cited by
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
“indications in mood disorders, either as anti-bipolar or adjunct antidepressant treatments (Derry and Moore, 2007; Philip et al, 2008).”
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200
Macfadden, W., Alphs, L., Haskins, J. T., Turner, N., Turkoz, I., Bossie, C., Kujawa, M., & Mahmoud, R. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00761.x · Cited by 178
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., Perry, P., Hertel, P., Such, P., Salzman, P. M., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11201 · Cited by 135
Sheehan, D. V., Harnett-Sheehan, K., Hidalgo, R. B., Janavs, J., McElroy, S. L., Amado, D., & Suppes, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.016 · Cited by 42
Metadata
- Authors
- Derry, S., & Moore, R. A.
- Venue
- BMC Psychiatry
- Published
- 2007-08-16
- Volume
- 7
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1965859008
- Cited by
- 93
- References
- 22
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. https://app.cochat.ai/papers/10.1186/1471-244x-7-40
- The paper
- Derry, S., & Moore, R. A. (2007). Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry. https://doi.org/10.1186/1471-244x-7-40
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.